Closed-Loop Insulin Delivery Effects on Glycemia During Sleep and Sleep Quality in Older Adults with Type 1 Diabetes: Results from the ORACL Trial.
Aged
Automated insulin delivery
Clinical trials
Closed-loop systems
Continuous glucose monitoring
Continuous subcutaneous insulin infusion
Pittsburgh Sleep Quality Index
Sensor-augmented pump therapy
Sleep
Type 1 diabetes
Journal
Diabetes technology & therapeutics
ISSN: 1557-8593
Titre abrégé: Diabetes Technol Ther
Pays: United States
ID NLM: 100889084
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
pubmed:
17
5
2022
medline:
9
9
2022
entrez:
16
5
2022
Statut:
ppublish
Résumé
Sleep-related effects of closed-loop therapy among older adults with type 1 diabetes have not been well established. In the OldeR Adult Closed-Loop (ORACL) randomized, crossover trial of first-generation closed-loop therapy (MiniMed 670G), participants wore actigraphy and completed sleep diaries for 14-day periods at stage end. During objectively measured sleep (actigraphy) with closed-loop versus sensor-augmented pump therapy, glucose time-in-range 70-180 mg/dL (3.9-10.0 mmol/L) was greater (90.3% vs. 78.7%, respectively; difference 8.2 percentage points [95% confidence interval {CI} 1.5 to 13.0];
Identifiants
pubmed: 35575751
doi: 10.1089/dia.2022.0110
doi:
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Insulin, Regular, Human
0
Banques de données
ANZCTR
['ACTRN12619000515190']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM